Anavex Life Sciences' (AVXL) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Anavex Life Sciences' stock is reaffirmed with a "sell (D-)" rating by Weiss Ratings, while other analysts have mixed ratings with targets ranging from $42.00 to $46.00.
• The company's shares traded down to $8.62, significantly lower than its 1-year high of $14.44, indicating a downward trend in stock performance.
• Anavex Life Sciences reported a quarterly loss of ($0.16) EPS, which missed analysts' expectations by $0.03.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report)'s stock had its "sell (d-)" rating restated by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

A number of other equities analysts have also recently commented on AVXL. D. Boral Capital reissued a "buy" rating and set a $46.00 price target on shares of Anavex Life Sciences in a report on Wednesday, October 1st. Wall Street Zen cut Anavex Life Sciences from a "hold" rating to a "sell" rating in a report on Saturday, August 23rd. Jones Trading reissued a "hold" rating on shares of Anavex Life Sciences in a report on Friday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $42.00 target price on shares of Anavex Life Sciences in a report on Tuesday, October 7th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $44.00.

Anavex Life Sciences Stock Performance

Shares of Anavex Life Sciences stock traded down $0.12 during trading on Friday, reaching $8.62. 803,436 shares of the company's stock were exchanged, compared to its average volume of 1,131,406. Anavex Life Sciences has a 1-year low of $5.22 and a 1-year high of $14.44. The company has a market cap of $740.37 million, a P/E ratio of -15.12 and a beta of 0.83. The firm's 50-day moving average price is $9.23 and its 200 day moving average price is $9.35.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.03). As a group, equities research analysts predict that Anavex Life Sciences will post -0.69 EPS for the current year.

Institutional Investors Weigh In On Anavex Life Sciences

A number of institutional investors have recently made changes to their positions in AVXL. LPL Financial LLC grew its position in shares of Anavex Life Sciences by 482.1% in the 1st quarter. LPL Financial LLC now owns 546,626 shares of the biotechnology company's stock valued at $4,690,000 after buying an additional 452,723 shares during the last quarter. Invesco Ltd. grew its position in shares of Anavex Life Sciences by 55.8% in the 2nd quarter. Invesco Ltd. now owns 863,959 shares of the biotechnology company's stock valued at $7,966,000 after buying an additional 309,605 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Anavex Life Sciences by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 4,902,246 shares of the biotechnology company's stock valued at $42,061,000 after buying an additional 221,802 shares during the last quarter. Nuveen LLC bought a new stake in shares of Anavex Life Sciences in the 1st quarter valued at about $1,622,000. Finally, Private Advisor Group LLC grew its position in shares of Anavex Life Sciences by 617.5% in the 1st quarter. Private Advisor Group LLC now owns 214,725 shares of the biotechnology company's stock valued at $1,842,000 after buying an additional 184,800 shares during the last quarter. Institutional investors own 31.55% of the company's stock.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.